An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PNH Phase 2 and Phase3 Studies With Iptacopan
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Iptacopan (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 30 Sep 2024 Planned End Date changed from 10 Jan 2028 to 19 Oct 2027.
- 30 Sep 2024 Planned primary completion date changed from 10 Jan 2028 to 19 Oct 2027.
- 13 May 2024 Planned End Date changed from 7 Feb 2028 to 10 Jan 2028.